The exploration of brain epigenomes, which consist of various types of DNA methylation and covalent histone modifications, is providing new and unprecedented insights into the mechanisms of neural development, neurological disease and aging. Traditionally, chromatin defects in the brain were considered static lesions of early development that occurred in the context of rare genetic syndromes, but it is now clear that mutations and maladaptations of the epigenetic machinery cover a much wider continuum that includes adult-onset neurodegenerative disease. Here, we describe how recent advances in neuroepigenetics have contributed to an improved mechanistic understanding of developmental and degenerative brain disorders, and we discuss how they could influence the development of future therapies for these conditions.
In a living cell, the functional definition of the human genome goes far beyond its linear sequence of 6 (or when haploid, 3) billion base pairs. The epigenome ('epi-' is derived from the Greek for 'over' or 'above') has a rich cache of highly regulated structural modifications of DNA cytosine, histone residues and histone variants, and, as such, defines the moldings and three-dimensional structure of the genomic material in the cell nucleus and provides the molecular bridge between genes and the environment. The epigenome is also responsible for orchestrating the myriad transcriptional units, condensed chromatin clusters and other features that distinguish the various cell types and the states of development or disease that share a genome within an individual (Boxes 1 and 2; Fig. 1) .
In this review, we describe how the field of epigenetics is reshaping the current thinking about neurological and neurodegenerative diseases. Only a few years ago, this field's primary focus was on a single mark-DNA methylation-in the context of cell division and early development. At first glance, these topics seemed to bear little relevance to the human postnatal or adult brain, which has a large proportion of postmitotic and highly differentiated cells and in which the majority of neurons develop, differentiate and permanently exit the cell cycle many weeks before birth. However, three recent major developments have prompted reconsideration of the potential importance of epigenetics in brain development and disease. First, studies in humans have indicated that the epigenetic landscape remains 'plastic' throughout all periods of brain development and aging and that ongoing dynamic regulation occurs even in neurons and other postmitotic constituents of the brain [1] [2] [3] [4] . Second, disordered chromatin organization and function have been ascribed key pathogenic roles not only in several neurodevelopmental syndromes of early childhood, but also in a subset of adult-onset hereditary neurodegenerative disorders 5, 6 . Third, a rapidly expanding repertoire of chromatin-modifying drugs has shown unexpected therapeutic potential for a wide range of degenerative and functional disorders of the nervous system [7] [8] [9] [10] [11] . These three lines of discovery have now coalesced, igniting an enormous interest in the chromatin-associated mechanisms of neurological disease and providing the foundations for a new discipline: 'neuroepigenetics' 12 .
Epigenetics and the mature brain Although the focus of this review is on epigenetic changes in various neurological diseases, the first issue to consider is whether the normal course of maturation and aging is associated with changes in the brain's epigenome (Box 1). The hypothesis that aging is associated with epigenetic changes in the brain is attractive, given that there are widespread age-related changes in gene expression in the cerebral cortex, including the downregulation of many neuronal genes 13, 14 . However, unlike the accumulation of somatic mutations and other structural DNA changes in the brain that affect promoter function during aging (and are likely to be irreversible) 15 , most or perhaps all epigenetic markings studied to date (Box 1) are now thought to be reversible, and there is no a priori reason for the unidirectional accumulation of a specific epigenetic mark in aging brain chromatin. Nonetheless, an increasing body of literature indicates that a substantial reorganization of the brain epigenome occurs during postnatal development and aging. The human cerebral cortex, for example, shows complex and gene-specific changes in the amounts of 5-methylcytosine (5-mC; cytosines are methylated at the 5 position carbon), and there is a steady rise in 5-mC at many promoters that continues into old age in conjunction with subtle changes (mostly declines) in the expression of transcripts originating from these promoters 2, 3 . Such age-related epigenetic drift could affect an individual's vulnerability to neurodegenerative disease. For example, in mouse cerebellum, the levels of the 5-mC derivative hydroxymethylcytosine (5-hmC; Box 1), are subject to a tenfold increase between postnatal week 1 and adulthood 16 . Notably, inhibitors substantially improves hippocampal-dependent learning and memory in aged mice 19 . It is possible that age-related drifts in brain epigenomes negatively affect neuronal 10, 15 and oligodendroglial 21 transcriptomes, thereby contributing to a decline in the signaling capacity of nerve cells, defects in axon myelination and other molecular alterations that have been linked to various cognitive disorders of the adult brain with and without neurodegeneration 14, 22 . Together, these findings leave little doubt that brain epigenomes are indeed subject to dynamic changes throughout all periods of maturation and aging, and this may have important implications for the neurobiology of disease.
Monogenetic neurological diseases associated with epigenetic changes Chromatin remodeling and the proper assignment of epigenetic marks on the genome are of fundamental importance for brain ontogenesis. These processes are also key control points in the stepwise transition from pluripotency to neural precursors to terminally differentiated neurons and glia 23 , and they are involved in developmental events such as neuronal migration and connectivity formation 24 . Perhaps unsurprisingly, more than a dozen neurological syndromes so far have been linked to mutations in single genes that encode DNA methyltransferase and histone modifying enzymes or their 'reader' proteins ( Table 1) . Notably, however, this list includes not only embryonic defects and multiorgan syndromes but also specific neurological disorders that show symptom onset in early childhood (for example, Rett syndrome) or neurodegeneration and regression beginning after adolescence (as in some cases of Kleefstra syndrome) or as late as the third or fourth decade of life (for example, hereditary sensory and autonomic neuropathy type 1, (HSAN1) with early-onset dementia; Table 1 ). The molecular defects in these rare monogenic causes of intellectual disability and adult-onset dementia could be used as a starting point to unravel the underlying among the genes that showed an increase in the amount of 5-hmC at their promoter during cerebellar maturation, pathways for aging-related neurodegenerative diseases and angiogenesis were overrepresented and included at least 15 genes linked to hereditary forms of spinocerebellar ataxia, a neurological syndrome defined by severe motor dysfunction with the degeneration of cerebellar Purkinje neurons and other systems 16 . It is also of interest that ten-eleven translocation (TET) proteins are responsible for converting 5-mC to 5-hmC; the active domains of these proteins belong to the same dioxygenase superfamily as hypoxia-inducible factor, an oxygen sensor that has been ascribed a key role in angiogenesis and oxidative-stress responses 16 . TET proteins may also function as oxygen sensors, thereby linking the epigenetic status of brain cells to (mal-)adaptive processes related to impaired tissue perfusion and oxygen supply.
In addition to changes in DNA methylation during development and aging, dynamic changes to the epigenetic landscapes of histone posttranslational modifications (PTMs) can also occur. An age-dependent regulation of histone-methylation markings that can differentiate between open and repressive chromatin has been documented for the human prefrontal and cerebellar cortex 17 , and hundreds of loci undergo substantial chromatin remodeling in cortical neurons between infancy and advanced age 4 . Furthermore, the brains of SAMP8 mice, which are prone to accelerated senescence and have learning and memory deficits, show age-related drifts in histone PTMs. These epigenetic drifts are defined by a loss of the markings associated with active gene expression, such as monomethyl histone H4 lysine 20 (H4K20me1) and H3K36me3 (Box 1 and Fig. 1 ), in conjunction with a robust rise in the repressive mark H3K27me3 (ref. 18) . Likewise, in the hippocampi of 16-monthold wild-type mice, genomic regions associated with actively expressed genes show a robust decline in acetylated H4K12 (ref. 19 ), a PTM that, like H3K36me3, is linked to the transcriptional elongation process 20 . In addition, upregulation of H4K12ac induced by histone deacetylase
Box 1 The organization and composition of the epigenome
The basic unit of chromatin is the nucleosome, which consists of 146 base pairs (bp) of genomic DNA wrapped around an octamer composed of the core histones H2A, H2B, H3 and H4. Chromatin fibers are defined as arrays of these nucleosomes, which are connected by linker DNA and linker histones (Fig. 1) . The combined set of DNA and histone modifications and histone variants provide the major building blocks for the epigenome 117, 118 .
DNA methylation. Two related, but functionally very different, types of DNA modification-methylation and hydroxymethylation of cytosine carbon 5, mostly in CpG dinucleotides-occur primarily within CpG-enriched islands (which are often defined by a GC percentage >50% across a minimum of 200 bp) 119 . The 5-mC and 5-hmC markings show a notably different distribution, with 5-hmC mostly confined to the 5ʹ ends of genes in amounts that correlate overall with gene-expression activity 120, 121 . In contrast, only a minute portion (<3%) of 5-mC locates to CpG islands at the 5´ ends of genes, where it is thought to function as a repressive mark; the remaining 97% is found in intra-and intergenic sequences and within DNA repeats 122 .
Post-translational histone modifications. According to recent studies, the number of residue-specific amino acid PTMs in a typical vertebrate cell may be as high as 130 (ref. 123) . PTMs include mono-, di-and trimethylation, acetylation and crotonylation, poly(ADP)-ribosylation and small-protein modification (by ubiquitin and small ubiquitin-like modifier, for example) of specific lysine residues, as well as arginine methylation and citrullination, serine phosphorylation, tyrosine hydroxylation and several others [123] [124] [125] . Various combinations and interrelations of these site-and residue-specific PTMs show close association with the functional architecture of chromatin, and specific epigenetic signatures have been identified for proximal promoters and gene bodies at sites of actual or potential transcription for enhancer and other regulatory sequences ( Fig. 1) and for condensed and silenced chromatin 126 .
Histone variants. Apart from the core histones H2A, H2B, H3 and H4, metazoan genomes encode a number of histone variants that provide another layer of epigenetic regulation. Some well-known variants include H3.3, H2A.Z and H2A.X, which, in contrast to the canonical histones, are subject to replication-independent expression and assembly 127 and have strong effects on nucleosome stability and compaction 128 .
Linker histones. These histones, such as H1, are crucial for the three-dimensional architecture of chromatin and the 'zigzag' arrangement of nucleosomes as regulators of linker-DNA folding, and the amounts of linker DNA strongly correlate with nucleosome repeat length 129 (Fig. 1) . Notably, the amounts of H1 in neurons are much lower than in most other cell types 129 , which explains the observation that the average nucleosome repeat length in rat neurons is 40 bp shorter than in glia (162 versus 201 bp) 130 . These neuron-specific features could have implications for disease vulnerability, because the RTT-associated protein MeCP2 competes with H1 for linker-DNA binding sites 131 and, furthermore, H1 levels are markedly increased in MeCP2-deficient brains 36 . r e v i e w npg MeCP2, which could compete with H1 for occupancy of linker DNA 36 , could also affect nucleosome repeat length and the general architecture of chromatin fibers ( Fig. 1 and Box 1) .
It was recently discovered that monogenetic brain disorders associated with defective DNA methylation are not limited to neurodevelopmental diseases; they also include some cases of HSAN1 (ref. 5), a rare neurodegenerative condition characterized by various neuropathies and onset of dementia in the third or fourth decade of life. The mutations associated with this condition are in the coding sequence of DNMT1 (encoding DNA (cytosine-5)-methyltransferase-1)-specifically, within the targeting sequence domain that is important for the nuclear localization and preferential enrichment of Dnmt1 at pericentric and other repeat DNA sites and for Dnmt1 activity and stability 5 . Indeed, peripheral blood cells from individuals with HSAN1 showed hypomethylation at DNA repeat sequences and subtle methylation imbalances (mostly hypomethylation) at hundreds of gene promoters 5 . Furthermore, additional mutations in close proximity to the targeting sequence domain of DNMT1 are found in some kindreds with autosomal dominant cerebellar ataxia, deafness and narcolepsy (ADCA-DN), which is also associated with early-onset dementia 6 . At first glance, it is surprising that these loss-of-function mutations in DNMT1 selectively affect postmitotic neurons. Dnmt1 functions as part of the DNA replication machinery during the S phase of the cell cycle and tracks the replication fork to remethylate the newly synthesized DNA strands 37 , mechanisms considered relevant only for dividing cells. However, Dnmt1 may also play a part in maintaining pathophysiology of these diseases, which could then open up hitherto unexplored therapeutic avenues for these specific conditions and eventually, perhaps, for a broader spectrum of neurological disease.
Mutations affecting DNA methylation and neurological disease. Hypomorphic (partial loss-of-function) mutations in DNMT3B, which encodes a DNA methyltransferase, are responsible for immunodeficiency, centromere instability and facial anomalies syndrome 1 (ICF1), a multiorgan syndrome that includes mental retardation and defective brain development 25, 26 . Cultured cells from subjects diagnosed with ICF show imbalances in repressive (5-mC and H3K27me3) and facilitative markings (H3K4me3 and H3K9ac) at pericentric DNA repeats 26 (those at the 'middle' portions of the chromosome that surround the centromere) and at hundreds of promoters throughout the genome (Fig. 1) . This imbalance is thought to contribute to the dysregulated expression of genes important for brain development, immune defense and many other key functions 27 . Hypomethylation defects also define ICF2, a nearly identical syndrome, but they occur at a different set of pericentric repeat sequences (Fig. 2) . ICF2 is caused by mutations in ZBTB24, which encodes a putative transcriptional repressor 28, 29 .
Mutations and structural variants in the X-linked gene MECP2, which encodes a methyl-CpG-binding protein, have been linked to Rett syndrome (RTT), a disorder of early childhood that has an incidence of 1 in 10,000 and is associated with developmental and cognitive regression as well as a broad range of neurological symptoms 30 . Males with RTT typically succumb during the perinatal period, but females survive, as they are somatic mosaics for the MECP2 gene owing to X-chromosome inactivation. Individuals with RTT usually appear grossly normal at birth and then develop symptoms typically before 2 years of age. Since the discovery of MECP2 mutations as a cause of RTT 30 , loss-of-function mutations and copy-number increases of the gene have been linked to various neurodevelopmental diseases, including childhood-onset schizophrenia and autism 31 . Studies in Mecp2 mutant mice have provided insights into an unexpectedly complex molecular pathophysiology and linked specific neurological RTT phenotypes to transcriptional regulation at specific promoter sequences (Box 3, Fig. 3 ). However, as with ICF, the chromatin pathology in RTT goes far beyond dysregulated promoter activity, and it is likely to involve pericentromeric repeats and other heterochromatic domains. For example, many individuals with RTT show decreased clustering of the chromocenters (which represent clusters of highly condensed chromatin) inside the nucleus, and Mecp2-deficient neurons in mice do not show the expected chromocenter expansions after induction of neuronal activity 32, 33 . Neuronal chromatin-which contains much higher amounts of MeCP2 than do glia 34, 35 -shows a global disorganization in Mecp2-deficient brains, with supranormal amounts of the linker histone H1, hyperacetylation of nucleosome core histones, and derepression of transcriptional activity at pericentromeric repeats, retrotransposons and other normally silent repeats 36 . Alterations in the amount of Katie Vicari r e v i e w npg structurally abnormal dendritic spines (a classical neuropathological abnormality found in various neurodevelopmental conditions) 43 and defective synaptic signaling in the frontal cortex 42 . However, the molecular mechanisms that link ATRX mutations to these neurological phenotypes remain unclear. One possible mechanism involves H3.3, a histone H3 variant that was first associated with active transcription but has subsequently been linked to ribosomal 44 , telomeric and pericentric repeats [45] [46] [47] (Fig. 2) . ATRX, together with its binding partner and histone chaperone, the death domain-associated protein Daxx, is essential for replication-independent H3.3 incorporation into nucleosomes [45] [46] [47] . It has been suggested that ATRX preferentially targets G-rich tandem repeats, which tend to form four-stranded, aberrant DNA structures called G-quadruplexes, and refolds them back into double-stranded DNA with a regular nucleosomal organization 44 .
Whether any of these mechanisms are relevant in the context of neurological disease remains to be investigated. Notably, however, there are at least three monogenetic disorders that show prominent epigenetic dysregulation of repeat DNA, including the ICF syndromes and ATRX (Fig. 2) . Further work will be required to clarify whether the observed chromatin defects at the sites of repeat DNA are indeed a casual factor for the disordered neurodevelopment common to these conditions. Furthermore, numerous deleterious mutations in genes encoding histone-modifying enzymes have been identified as monogenetic causes of neurodevelopmental or neurodegenerative disease ( Table 1) .
Disordered chromatin in neurodegenerative disease
Historically, studies of chromatin structure and function-and epigenetically driven concepts in general-have received little attention from researchers exploring the pathophysiology of slowly progressing neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's diseases. Two independent lines of discovery have now the amount of DNA methylation in quiescent and even postmitotic cells, as it remains enriched at pericentric repeats and other condensed portions of the genome after S phase is complete 38 . Because this cell cycle-independent function of Dnmt1 is dependent on its having an intact targeting sequence domain 38 , one could speculate that the deleterious DNMT1 mutations in individuals with HSAN1 result in faulty chromatin remodeling at repeat sequences of differentiated cells, including neurons. Notably, mutant mice that are mosaic for a prenatal deletion of Dnmt1 in neural precursors lose virtually all of their brain cells with DNA hypomethylation within 1 month after birth 39 , and it will be interesting to find out whether similar phenotypes emerge in animals in which Dnmt1 mutations are limited to the portions of the targeting sequence domain that are mutated in HSAN1 pedigrees.
It is remarkable that each of these neurological conditions involving dysregulated DNA methylation-ICF, RTT and HSAN1-is associated with widespread chromatin defects across the genome of differentiated cells in the central nervous system, including pericentric and other repeat-rich domains that have, until now, been barely explored in the neurosciences. Future developments in this area will be very interesting to follow, and they are likely to shed more light on the role of epigenetic regulation of these repeat DNAs in healthy and diseased brains. Heritable brain disorders with histone defects. Loss-of-function mutations in ATRX, which encodes a multifunctional chromatin regulator, are responsible for various X-linked mental-retardation syndromes 40 . ATRX protein expression increases progressively during brain development, and in mice, Atrx ablation results in excessive apoptosis and defective migration of young neurons 40, 41 . One Atrx mutant mouse line, which has a deletion in the ATRX zinc-finger motif, is a genetic model for humans who have a milder form of X-linked mental retardation 42 . This mouse model shows impaired learning behaviors as well as elongated, r e v i e w npg DNA methylation at the promoters of several disease-associated genes, including the one encoding a-synuclein itself 50 . There is additional, indirect, evidence that the delicate balance in the amounts of Dnmt1 and other DNA methyltransferases, including Dnmt3a, inside the nuclei of brain cells plays an important part in neuronal health and function. For example, the in vivo induction of apoptosis in motor neurons by toxic drugs or peripheral nerve lesions is associated with a preapoptotic rise in the amounts of Dnmt1 and Dnmt3a in the cell nucleus 51 . Furthermore, the amounts of methylcytosine and expression of DNMT are reportedly increased in pyramidal neurons in the cerebral cortex of subjects diagnosed with the sporadic motor-neuron disease amyotrophic lateral sclerosis 51 . Adding further complexity, there is evidence that Dnmt1 and Dnmt3a are not only targeted to the nucleus but also abundant in mitochondria, including those that are localized in distal neuronal processes and synapses 51 . Whether or not these DNA methyltransferases regulate mitochondrial functions in brain cells remains to be investigated, but preliminary evidence suggests that mitochondrial DNA, like nuclear DNA, is subject to methylation and hydroxymethylation of its cytosine residues 52 . Likewise, histone-modifying enzymes could play a part in neurodegenerative disease. Because much of the evidence so far has been correlative, the neuroepigenetics field eagerly awaits further work to confirm (or refute) a key role for histone-modifying enzymes in the etiology or progress of neurodegenerative disorders. For example, the pathological sequestration of transcription factors vital for neuronal health, such as the cAMP response element-binding protein CREB and its binding partner CBP 48, 53 (which encodes a histone acetyltransferase and is associated with Rubinstein-Taybi syndrome; Table 1 ), has also been linked to moved epigenetics toward center stage in these fields. First, initial reports of the therapeutic benefits of histone deacetylase-inhibitor drugs in the nervous system used preclinical models for Huntington's disease, a hereditary condition caused by the excessive expansion of a CAG repeat in the huntingtin gene 48, 49 . Second, the genetic findings described above link rare types of adult-onset dementia associated with hereditary neuropathy 5 or cerebellar ataxia 6 to deleterious mutations in proteins that regulate DNA or histone methylation. These findings may imply that other, more common types of adult-onset neurodegenerative disease could also be related to the defective regulation of chromatin in the brain.
Indeed, 'synucleinopathies' such as Parkinson's disease and dementia with Lewy bodies are associated with loss of Dnmt1 from the cell nuclei in the brain, both in patients with these conditions and in transgenic mice that overexpress synuclein 50 . This loss leads to deregulation of 
Three examples of monogenetic brain disorders associated with defects in heterochromatin are shown. Mutations in genes encoding Dnmt3b (associated with the disorder ICF1) or ZBTB24 (associated with the disorder ICF2) result in hypomethylation of different types of pericentric satellite (sat) repeats 28, 106 . The multifunctional chromatin regulator ATRX controls the incorporation of the variant histone H3.3 not only into nucleosomes surrounding the transcription start sites of active genes, but also at various repeat sequences. Loss-of-function mutations in ATRX have been associated with X-linked mental-retardation syndromes.
Box 2 Readers, writers and erasers of chromatin marks
It is still under debate whether the epigenome's constituents play a causal part in establishing functional chromatin states. For example, the presence of open chromatin-associated histone modifications and variants at a specific locus in the genome is thought to reflect a process driven by transcriptional regulation and dynamic repositioning of nucleosomes. From this perspective, at least some DNA and histone modifications may function merely as 'cogs' in the chromatin-remodeling machinery rather than as key drivers 132 . Whatever the importance of DNA and histone modifications in regulating the chromatin-remodeling process, an increasing number of molecules that attach ('writers') or erase modifications to DNA or histone modifications or that bind ('readers') to a specific epigenetically modified site have emerged as key players in the pathophysiology and potential treatment of neurological disease. Most, or virtually all, epigenetic markings that have so far been studied in brain are subject to bidirectional and potentially highly dynamic regulation in the context of neuronal activity and various other paradigms 133, 134 .
The underlying molecular machineries that contribute to the epigenome are often complex; for example, the DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b establish and maintain DNA-methylation marks. The actions of these enzymes are counterbalanced by active demethylation pathways involving 5-mC hydroxylation and oxidation via TET dioxygenases or by deamination of 5-mC or 5-hmC mediated by activation-induced deaminase and the enzyme APOBEC followed by base-excision repair-mediated replacement with (unmethylated) cytosine 135, 136 . Other systems show a surprising degree of diversity, or perhaps redundancy, at the genetic level. For example, the various families of histone methyltransferases and demethylases together could easily account for >100 genes in a mammalian genome 137, 138 .
Proteins that bind to a specific epigenetic mark are defined by their characteristic reader module; well-studied examples include the methyl-CpG-binding domain for 5-mC-DNA, the bromodomain for lysine acetylation, the chromodomain and tudor, MBT, WD40-repeat and PHD-finger domains, which target methylated lysines or arginines in a residue-specific manner 125 . Conversely, specific methyllysine marks could be targeted by 50-100 reader proteins. For the open-chromatin mark H3K4me3, the reader proteins include many components of the RNA polymerase II-associated transcriptional initiation complex, whereas other marks, such as H3K9me3, are primarily targeted by transcriptional repressors and regulators of chromatin condensation 139 .
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r e v i e w npg further boosted by the recent US Food and Drug Administration (FDA) approvals for the potent histone deacetylase inhibitors (HDAC inhibitors) suberoylanilide hydroxamic acid (SAHA, trade name Vorinostat) and romidepsin (trade name Istodax) in the treatment of hematological malignancies. Indeed, a large body of preclinical work has suggested that HDAC inhibitors could have therapeutic potential in a wide range of neurological conditions. These include acute brain injury and stroke paradigms, various neurodegenerative conditions such as Parkinson's and Alzheimer's disease, motor-neuron and triplet-repeat diseases such as Huntington's and spinocerebellar ataxias [8] [9] [10] [11] and depression and other psychiatric illnesses [62] [63] [64] (Table 2) . But it is still unclear whether HDAC inhibitors would benefit the patients affected by any of these conditions. Moreover, like their counterparts-the histone acetyltransferases, or HATs-class I and II HDACs (commonly defined by their zinccontaining catalytic domain) and the class III HDACs or sirtuins (which are nicotinamide NAD + dependent) regulate lysine acetylation of nonhistone proteins 65, 66 . Indeed, nonhistone targets of sirtuin 1 (SIRT1) are thought to mediate its neuroprotective and cognitive phenotypes 67, 68 . Such promiscuity for their target proteins adds further complexity to the interpretation of the therapeutic potential of HDACs that has emerged in models of neurological disease. Consider the example of frontotemporal dementia (FTD), a genetically heterogeneous neurodegenerative condition that primarily affects the frontal lobes and is associated with at least three different types of inclusion bodies in brain tissue 69 . Haploinsufficiency for GRN, which encodes progranulin, underlies a the b-amyloid plaques seen in the brains of individuals with Alzheimer's disease 54 and the polyglutamine aggregates and nuclear inclusions in Huntington's chorea 55 . Furthermore, a hyperactivity of tissue transglutaminase-2 in Huntington's disease leads to excessive nuclear amounts of lysine e-amino-glutamine g-carboxamide bonds, which are resistant to proteolysis 56 . This excess results in an abnormal configuration of nuclear actin-cofilin complexes 57 and potentially abnormal histone polyamination, which leads to defective expression of PGC1-a, a transcription factor with an essential role in mitochondrial biogenesis 58 . Furthermore, excessive H3K9 methylation 59 and increased expression of macroH2A1, a variant histone broadly associated with repressive chromatin remodeling 60 , have been observed in blood and brain tissues from individuals with Huntington's disease, including the striatum and frontal cortex, which are heavily affected by the underlying neurodegenerative process in this disease. Such changes, in conjunction with additional defects in nucleosomal structure and function, may contribute to the decreased expression of the neurotrophic factor BDNF, dopamine receptors, MAP kinase signaling components and other transcriptional changes that have been observed in the striata of people with Huntington's disease 61 . Clearly, the hypothesis that histone-modifying enzymes are involved in the pathophysiology of neurodegenerative diseases warrants further investigation.
Epigenetic targets in the treatment of neurological disease Histone acetylation. There is great enthusiasm in academia and industry about the development of new epigenetic therapies, and this has been
Box 3 The complex pathophysiology of MeCP2
Among the growing list of genes associated with a brain-specific chromatin disorder, the largest share of the literature relates to the gene MECP2. The following discussion on emerging views of MECP2-associated transcriptional (dys-)regulation exemplifies the challenges and complexities in the endeavor to identify and pinpoint the molecular pathology of even a monogenetic disease.
Studies in both humans and mice have shown that phenotypic consequences arise when the amounts of functional MeCP2 protein drop below or rise above its normal amounts in brain 140 . Recent comparisons of the transcriptomes from gain-and loss-of-function Mecp2 mutant mice to those from wild-type mice have provided some insights into the complexities of MeCP2-mediated transcriptional regulation at specific promoter sequences. These studies have also implicated specific transcriptional changes in some of the emotional and behavioral changes that have been observed across the clinical spectrum of MECP2 mutations. For example, in the basal forebrain, including the amygdala, more than 32 genes with established roles in the regulation of anxiety and social behaviors-including the neuropeptide corticotropin-releasing hormone (Crh) and the G protein-coupled µ-opioid receptor (Oprm1)-were highly sensitive to Mecp2 gene dosage 141, 142 . In particular, elevated anxiety in mice that overexpress Mecp2 is thought to be directly related to increased MeCP2 binding and upregulated transcription at the Crh and Oprm1 genes 141 . Conversely, decreased anxiety in some Mecp2 loss-of-function mutants has been linked to gene-expression changes, including decreased expression of Crh 142 .
Taken together, these results seem counterintuitive to initial descriptions of MeCP2's role as a transcriptional repressor; adding to the complexity, neuronal activity induces MeCP2 phosphorylation at multiple serine sites, thereby altering the protein's affinity to its target gene promoters 143 . In vivo, ablation of a phosphoserine site downstream of MeCP2's transcriptional repression domain (S421) enhanced binding of MeCP2 to the Bdnf promoter, resulting in increased neurotrophin expression and improved hippocampal learning and plasticity 144 (see Figure) . Thus, a highly complicated and multilayered process is involved in fine-tuning MeCP2 expression, which in turn controls many genes that have key regulatory roles in higher-order behaviors. 
5-mC
Fine-tuning of MeCP2 function and higher-order behavior. In adult mouse forebrain, promoter-bound MeCP2 upregulates the expression of key regulatory factors that control emotional and affective states, learning and memory. In vivo, phosphorylation (P) of MeCP2 Ser421 decreases promoter binding and gene expression, with corresponding changes in behavioral states. These observations were established by work in the amygdala (blue), hypothalamus (purple) and hippocampus (green) of Mecp2 mutant and wild-type mice.
Marina Corral r e v i e w npg
Because multiple BET reader proteins, including BRD1, BRD2 and BRD3, show robust and widespread expression in the mature mouse brain 83 (http://www.brain-map.org/), it will be interesting to explore bromodomain inhibitors in the context of some of the neurological disease models discussed above. As with the drugs that target HATs and HDACs, the specificity and side-effect profiles of bromodomain inhibitors will also require additional investigation.
Histone methylation. The clinical potential of drugs that can interfere with the regulation of histone methylation is also a promising, albeit largely unexplored, field. There are probably up to 100 histone methyltransferases and demethylases encoded in the human genome, and many of these enzymes are defined by functional domains outside the catalytic sites that are thought to contribute to target specificity and genomic occupancy patterns 7 . Like the HDAC inhibitors, a subset of histone methyltransferase inhibitors are in clinical trials for cancer treatment and are likely to be explored in the context of neurological disease in the near future 7 . An interesting candidate is the small molecule BIX-01294, which is an inhibitor for the histone H3K9-specific methyltransferases G9a and Glp 84 . This drug derepresses neuronal gene expression 84 and, when administered directly into the ventral striatum (a key structure in the brain's addiction circuitry), strongly enhances the development of reward behaviors in mice exposed to the stimulant drug cocaine 85 . It remains to be determined whether BIX-01294 elicits learning-and memory-enhancing effects outside of the stimulant addiction paradigm. However, it is interesting to note that the drug's mechanism of action could, at least in part, involve the inhibition of G9a-and Glp-mediated repressive chromatin remodeling at the promoters of Bdnf, Cdk5, Arc and other genes that function as key regulators for spine density and synaptic connectivity in the mouse brain 85 .
DNA methylation. Several inhibitors of DNA methylation, including the cytidine analogs 5-azacytidine and zebularine and nucleoside analogs that sequester Dnmt enzymes after being incorporated into DNA 86 , have been well characterized and are approved or are in preclinical and clinical trials for the treatment of cancer 86 . When administered directly into the brain tissue of mice and rats, these and other Dnmt inhibitors type of FTD that is defined by brain inclusions containing TAR DNAbinding protein 43 (ref. 69) . Notably, GRN expression is robustly upregulated by SAHA, which has been suggested as a promising treatment for FTD 70 . In contrast, FTD with parkinsonism-17 (FTDP-17) is defined by the abnormal accumulation, caused by excessive acetylation, of the microtubule-binding protein tau in the brain 71 . Thus, blocking of tau acetylation by inhibiting CBP and promotion of tau deacetylation via activation of SIRT1 has been proposed as a new therapeutic avenue to treat FTDP-17 and other 'tauopathies' such as Alzheimer's disease 71 . Upregulation of SIRT1 also suppresses b-amyloid production in the brains of mouse models of Alzheimer's disease 72 . Notably, however, the pan-sirtuin inhibitor nicotinamide also has therapeutic benefit in a transgenic Alzheimer's mouse model that overexpresses tau 73 . Although nicotinamide is a fairly broadly acting drug that has many effects beyond sirtuin inhibition, a subset of SIRT2-specific inhibitors elicits therapeutic benefits in cultured human cells and in Drosophila models of Parkinson's disease 74 . Thus, depending on the type of neurodegenerative disease and the specific HDACs and HATs involved, modulation of HDAC and HAT activity could have very different and potentially opposing clinical implications. Furthermore, although HDAC inhibitors are generally considered to promote neuronal growth and differentiation, there is also evidence that they could have potentially detrimental effects on the orderly maturation of astrocytes and oligodendrocytes [75] [76] [77] . Therefore, caution is warranted in evaluation of the potential benefits of these drugs in multiple sclerosis 76 , white-matter ischemia 9 and other neurological conditions that involve the damage or injury of the brain's non-neuronal cellular constituents. In addition, activation of retrotransposons that are normally epigenetically silenced could be another potentially detrimental side effect of HDAC inhibitors 78 (Box 4). In addition to HAT and HDAC activators or inhibitors, other types of drugs that interfere with histone acetylation pathways have recently emerged. For example, the bromodomains of the BET protein family, which are classical 'readers' of acetylated chromatin and facilitate transcriptional activation 79 , can be targeted by highly specific small-molecule inhibitors that have been shown to correct transcriptional dysregulation in hematopoietic and solid malignancies 80, 81 , inflammation and other medical conditions previously shown to be HDAC inhibitor sensitive 82 . 96 Yes r e v i e w npg treatment with Dnmt inhibitors can confer stroke protection after mild ischemia; furthermore, haploinsufficiency for Dnmt1 in mice is associated with smaller infarction volumes after acute ischemia and stroke 93, 94 .
A recent study reported a strong, antiapoptotic effect for RG 108 in an injury-based mouse model of amyotrophic lateral sclerosis 51 .
Topoisomerase inhibitors. Topoisomerases are DNA-cleaving enzymes that are important in the processes of replication and recombination, transcription and chromatin remodeling 95 . A recent study using an unbiased high-content screening approach in mouse primary cortical disrupt synaptic plasticity and hippocampal learning and memory, and they are powerful modulators of reward and addiction behaviors [87] [88] [89] [90] . But nucleoside analogs are thought to act primarily at sites of DNA synthesis and replication during the cell cycle; thus, they seem at first glance to be of little relevance to postmitotic neurons and glia. Notably, n-phthalyl-l-tryptophan (RG 108) and other drugs that interfere with sites at which Dnmt is active independently of DNA replication still elicit a robust impairment of hippocampal learning and memory 91, 92 . The potential of drugs that interfere with Dnmt activity may go beyond these examples of synaptic and behavioral plasticity. In mice, for example,
Box 4 Epigenetic control of the brain's 'jumping genes'
Retrotransposons, or 'jumping genes', are commonly defined as mobile elements that can proliferate in the germline of plants and mammals and thus contribute to the potential for massive genome expansion during the course of evolution 145 . Approximately 40-50% of the human genome is derived from mobile elements and, more importantly, several classes of retrotransposons, which duplicate via RNA intermediates and then are inserted into a different site of the genome, remain active even in modern humans 146 . Some of the best-known examples of retrotransposons include LINE-1 (L1), Alu and SVA elements 146 , and it is probable that new insertions by these elements contribute to genome plasticity in individual brain cells 147 . In particular, the hippocampus and striatum are defined by much higher rates of de novo retrotransposition than other somatic tissues, such as blood, heart and liver 147, 148 . It has been estimated that each hippocampal cell could harbor up to 800 new insertions, indicating a hitherto unexpected degree of genomic plasticity 148 . Notably, both L1-and Alubased insertion events into human brain genomes disproportionally affect actively expressed genes, including many that are pivotal for synaptic transmission, such as those encoding the dopamine receptor DRD3, the amino acid transporters SLC6A5, SLC6A6 and SLC6A9 and the RAI1 transcription factor, which has been implicated in schizophrenia and 17p11.2 (Smith-Magenis) deletion syndrome 147 . Therefore, retrotransposon activity could contribute to neuronal diversity 149 and even drug-or experience-dependent plasticity 150, 151 (Fig. 4) . Insertional mutagenesis could also have potentially detrimental consequences, such as the aberrant activation or repression of neighboring genes, exon shuffling and gene deletions 149 . Epigenetic regulators are vital for a cell's ability to suppress retrotransposon activity, and L1, Alu and other elements that utilize the L1 replication machinery are epigenetically silenced via repressive DNA methylation and histone modifications 152 . Therefore, when repressive chromatin remodeling at sites of mobile elements is 'exchanged' with transcriptional-activation complexes, as when the WNT3a-b-catenin complex binds to the L1 promoter 153, 154 , excessive amounts of insertional mutagenesis could cause cell damage. For example, loss of the repressive DNA-methylation reader protein MeCP2 in neural cultures or in the brains of mice with MECP2 mutation results in a modest excess of L1 activity 36, 155 in conjunction with changes in global chromatin states (see Figure) . Increased L1 retrotransposition was also recently detected in cells from people with ataxia telangiectasia, an autosomal recessive neurodegenerative condition caused by alterations of the DNA damage sensor and the serine/threonine kinase ATM 78 . Loss of ATM results in increased reverse transcriptase efficiency, thereby fostering new L1 insertions in the genome 78 . It is conceivable that RTT and ataxia telangiectasia are merely the 'tip of the iceberg' and that numerous other neurological conditions with links to transposon dysregulation may emerge in the near future. Whatever the underlying mechanism of action, we predict that, as in the fields of oncology and general medicine (which are now pursuing hundreds of clinical trials with epigenetic drug targets), the treatment options for neurodevelopmental and neurodegenerative diseases will soon be enriched by the array of chromatin compounds that are emerging from preclinical and translational research ( Table 2) .
neurons discovered that a diverse group of molecules that function as inhibitors of topoisomerase I or II can unlock the expression of the normally epigenetically silenced paternal allele of Ube3a, which encodes ubiquitin protein ligase E3A. These topoisomerase inhibitors mediate their effects by reducing the expression of the imprinted Ube3a antisense RNA (Ube3a-ATS) 96 . The expression of this antisense RNA is normally repressed on the maternal chromosome in conjunction with the allelespecific DNA methylation of an imprinting center (which is a DNA or chromatin structure that carries epigenetic information about parental origin) 97 . Like hundreds of other loci defined by parent-of-origin-specific gene expression, Ube3a has been considered epigenetically stable throughout life 98 . This hypothesis now needs to be revised, however, given that even a single intrathecal infusion of the FDA-approved topoisomerase inhibitor topotecan was sufficient to relieve silencing of the paternal Ube3a (sense) transcript in the lumbar spinal neurons of mice for at least 3 months 96 . The most obvious explanation for topotecan's mechanism of action-altered DNA methylation of the Ube3a imprinting center-has been ruled out. Thus, the underlying mechanism(s) remain a mystery. The reactivation of paternal UBE3A expression via topoisomerase inhibition could provide a starting point for investigation of potential therapies for Angelman syndrome, a neurodevelopmental disorder that is caused by loss-of-function mutations and deletions at the maternal UBE3A locus [99] [100] [101] and for which there are now no effective treatments. Although it is not known at present whether topoisomerase-mediated reversal of imprinting-related gene expression is specific to the UBE3A locus, this issue could be addressed by, for example, fusing topoisomerase enzymes to customized motifs for sequence-specific binding at UBE3A. For example, chimeric zinc-finger nucleases or transcription activatorlike (TAL) effectors of plant pathogenic bacteria have been fused to the FokI restriction enzyme, allowing the induction of 'custom-made' DNA strand breaks at specific and even at unique loci in the genome 102, 103 . It is certainly worth exploring whether similar strategies could be used to create a chimeric protein comprised of a topoisomerase enzyme fused to a custom-made zinc-finger or TAL effector sequence that can specifically target the UBE3A imprinting center.
outlook
The field of neuroepigenetics is evolving at a rapid pace. We are beginning to understand more about the neural mechanisms that mediate the reversible and bidirectional regulation of DNA methylation and various histone modifications. Furthermore, as discussed in this review, the epigenetic dysregulation of gene expression and chromatin architecture could play a prominent part in the pathophysiology of various neurological disorders. However, in many of these disease conditions the mutant epigenetic regulator seemingly operates in a highly complex and multifunctional manner at a large number of genomic loci. For example, RTT, ICF1, ICF2 and HSAN1 are examples of a heterogeneous group of neurodevelopmental and neurodegenerative disorders caused by alterations in proteins that 'read' or 'write' DNA methylation, and each disease shows disordered DNA methylation at numerous single-copy genes as well as in specific sequences of repeat DNA in subdomains of constitutive heterochromatin. It will be important to clarify, for each disorder, which of the genomic loci affected are important for the manifestation, progression and potential treatment of disease, and which are merely bystanders, irrelevant to the disease process.
For the numerous chromatin-modifying drugs that have shown promise in preclinical studies, it will be important to pinpoint their key mechanisms of action. For example, are the beneficial effects of HDAC inhibitors in various acute and chronic neurodegenerative and cognitive disorders due to their broad effects on histone modifications, changes in
